Effect of Implant Position on Magnetic Resonance Image Distortion

Status Completed

Clinical Trial Summary

Patients with Neurofibromatosis type 2 (NF2) almost always develop acoustic neuromas in both ears. As a result of the tumours themselves or the treatment of the tumours, many patients become profoundly deaf in both ears. It is possible to restore a degree of hearing by placing a hearing implant in the brainstem adjacent to the hearing pathways within the brain. This is termed an auditory brainstem implant (ABI).

The aim of this study is to find the optimum head position in relation to the MRI magnet field, which would produce least area of image distortion in patients with ABIs. This will be of benefit in optimising the MR imaging in future patients with implants.

Clinical Trial Description

Auditory brainstem implants (ABI) are placed against the auditory centres in the brainstem if it is not possible to implant the cochlea or if the cochlear nerve, which conveys neural signals from the cochlea to the brainstem, is damaged or absent. The latter device is usually used in patients with Neurofibromatosis type 2 (NF2) who develop bilateral benign inner ear tumours called vestibular schwannomas as well as other neurological tumours1. These patients often become bilaterally profoundly deaf either as a result of the disease or because of surgery to remove the tumours and require an ABI.

Patients with NF2 require monitoring of their tumours. In the absence of an auditory implant it is possible to use magnetic resonance imaging. This is the gold standard imaging technique as it gives excellent views of the soft tissues of head. However, there has been concern regarding the use of MRI in patients with auditory implants until recently because of potential problems such as demagnetisation of the magnet within the implant, implant magnet displacement and risk to the integrity of the implant electronics. In addition, the magnet field of the implant magnet results in imaging artefact (manifesting as a signal void) around the implant site that limits the information that can be obtained. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02246231
Study type	Interventional
Source	Manchester University NHS Foundation Trust
Contact
Status	Completed
Phase	N/A
Start date	February 3, 2014
Completion date	January 31, 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05521048` - Doxycycline in Cutaneous Schwannoma (NF2)	Phase 1/Phase 2
Completed	`NCT01207687` - Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)	Phase 2
Completed	`NCT01767792` - Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas	Phase 2
Active, not recruiting	`NCT01552434` - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease	Phase 1
Completed	`NCT01880749` - Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas	Early Phase 1
Recruiting	`NCT05130866` - Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas	Phase 2/Phase 3
Recruiting	`NCT04374305` - Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)	Phase 2
Completed	`NCT01125046` - Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas	Phase 2
Completed	`NCT03210285` - WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data
Completed	`NCT02934256` - Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors	Phase 2
Terminated	`NCT01345136` - Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma	Phase 2
Completed	`NCT02104323` - Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors	Phase 2
Terminated	`NCT02282917` - Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma	Early Phase 1
Completed	`NCT02129647` - Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas	Phase 2
No longer available	`NCT02589912` - Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.